-
Posted by
Two Blokes Jun 17 -
Filed in
Stock
-
5 views
Eli Lilly and Co (NYSE:LLY) is in advanced discussions to acquire Verve Therapeutics in a deal worth up to $1.3 billion, according to the Financial Times. The proposed terms include a nearly $1 billion upfront payment, with an additional $300 million contingent on clinical milestones.
